One first-line approach to differentiate between Lynch syndrome and sporadic cancer is to use immunohistochemical (IHC) staining to assess MLH1, MSH2, MSH6, and PMS2 protein expression in tumor tissue from biopsy or surgical resection. Here, MLH1 is linked to Lynch syndrome.